Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2011

View Archived Issues

Novartis offers overview of first quarter 2011

Cel-Sci receives approval to enroll patients in Canada in phase III Multikine trial

Merck & Co. discloses new NO-linked cicletanine derivatives

Novel xanthine oxidase inhibitors claimed by LG Life Sciences

Humanized monoclonal antibody XGFR-4 targets two signaling pathways in cancer

Antibody 12D7 shows therapeutic efficacy against cancer in combination with chemotherapy

Phase I and II data presented on ophthalmic agent SAR-1118

Bifunctional immune-mobilizing fusion proteins redirect immune system to destroy cancer cells

BAY-87-2243 suppresses tumor growth in vivo by targeting hypoxia-induced HIF1-alpha activation

Achaogen patents novel antibacterial aminoglycoside derivatives

Merck & Co. discloses new inhibitors of beta-secretase 1 and 2

Geron receives funding from CIRM for development of GRNOPC-1

IntraCellular Therapies reports novel radiolabeled PDE1 inhibitors

Karolinska Institutet presents novel series of selenium-containing antioxidants

Omeros' phosphodiesterase 7 inhibitors show preclinical efficacy in nicotine addiction

Algeta and Affibody to develop thorium-based tumor-targeting alpha pharmaceuticals

Revatio approved in E.U. for treatment of pulmonary arterial hypertension in children

Two-thirds of patients now enrolled in Serdaxin phase IIb trial

ImmunoCellular Therapeutics updates long-term data from phase I ICT-107 trial in glioblastoma

MMRF and Astellas Pharma Global Development to jointly develop OSI-906 in multiple myeloma

Advanced Life Sciences terminates staff and suspends operations

Oxford BioMedica and Pfizer expand licensing agreement for 5T4 antibody

Selexys Pharmaceuticals begins enrollment in phase I SelG1 study

AVI BioPharma begins phase I studies of AVI-6002 and AVI-6003

S*BIO regains rights to SB-1518 and SB-1578 from Onyx Pharmaceuticals

Santaris Pharma advances SPC-5001 to phase I for hypercholesterolemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...